Compare KR & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KR | RMD |
|---|---|---|
| Founded | 1883 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 36.8B |
| IPO Year | 2007 | N/A |
| Metric | KR | RMD |
|---|---|---|
| Price | $75.62 | $230.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $74.25 | ★ $293.70 |
| AVG Volume (30 Days) | ★ 6.1M | 889.3K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.87% | 1.03% |
| EPS Growth | ★ 23.99 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $147,123,000,000.00 | N/A |
| Revenue This Year | $5.52 | $10.64 |
| Revenue Next Year | $1.92 | $7.38 |
| P/E Ratio | $325.70 | ★ $25.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $58.60 | $199.92 |
| 52 Week High | $76.58 | $293.81 |
| Indicator | KR | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.75 | 29.47 |
| Support Level | $65.02 | N/A |
| Resistance Level | N/A | $260.21 |
| Average True Range (ATR) | 2.07 | 5.64 |
| MACD | 0.46 | -2.88 |
| Stochastic Oscillator | 90.31 | 0.73 |
Kroger is one of the largest grocery retailers in the United States with about 2,700 stores across a portfolio of more than 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The company also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.